Inoperables malignes Melanom: Relatlimab wird Option für die Erstlinie
Keyword(s):
2013 ◽
Vol 41
(03)
◽
pp. 190-194
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):